[Optimizing treatment of advanced urologic malignancies]

Urologe A. 2007 Sep;46(9):1278-84. doi: 10.1007/s00120-007-1396-4.
[Article in German]
No abstract available

MeSH terms

  • Carcinoma, Transitional Cell / genetics
  • Carcinoma, Transitional Cell / pathology
  • Carcinoma, Transitional Cell / therapy
  • Docetaxel
  • Drug Resistance, Neoplasm
  • Education, Medical, Graduate
  • Gene Expression Profiling
  • Humans
  • Lymphatic Metastasis
  • Male
  • Neoplasm Staging
  • Neoplasms, Germ Cell and Embryonal / genetics
  • Neoplasms, Germ Cell and Embryonal / pathology
  • Neoplasms, Germ Cell and Embryonal / therapy
  • Palliative Care
  • Prognosis
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy
  • Quality Assurance, Health Care
  • Research / education
  • Taxoids / therapeutic use
  • Testicular Neoplasms / genetics
  • Testicular Neoplasms / pathology
  • Testicular Neoplasms / therapy
  • Transurethral Resection of Prostate
  • Urinary Bladder Neoplasms / genetics
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / therapy
  • Urologic Neoplasms / genetics
  • Urologic Neoplasms / pathology
  • Urologic Neoplasms / therapy*
  • Urology / education

Substances

  • Taxoids
  • Docetaxel